Trivium Point Advisory LLC Increases Stock Holdings in AbbVie Inc. $ABBV

Trivium Point Advisory LLC increased its stake in shares of AbbVie Inc. (NYSE:ABBV) by 110.9% during the 2nd quarter, according to its most recent filing with the SEC. The institutional investor owned 10,728 shares of the company’s stock after acquiring an additional 5,641 shares during the period. Trivium Point Advisory LLC’s holdings in AbbVie were worth $2,700,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. State Street Corp boosted its holdings in AbbVie by 1.4% in the fourth quarter. State Street Corp now owns 80,940,931 shares of the company’s stock valued at $18,494,193,000 after purchasing an additional 1,119,274 shares during the last quarter. Geode Capital Management LLC increased its holdings in AbbVie by 10.4% during the 4th quarter. Geode Capital Management LLC now owns 44,629,980 shares of the company’s stock worth $10,179,099,000 after purchasing an additional 4,190,487 shares during the last quarter. Bank of America Corp DE raised its position in shares of AbbVie by 1.4% in the 4th quarter. Bank of America Corp DE now owns 25,824,399 shares of the company’s stock valued at $5,900,617,000 after purchasing an additional 356,394 shares in the last quarter. Norges Bank purchased a new position in shares of AbbVie during the 4th quarter valued at approximately $5,865,055,000. Finally, Capital Research Global Investors boosted its stake in shares of AbbVie by 0.7% during the 4th quarter. Capital Research Global Investors now owns 25,408,200 shares of the company’s stock valued at $5,805,530,000 after buying an additional 177,370 shares during the last quarter. Hedge funds and other institutional investors own 70.23% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts recently issued reports on ABBV shares. Erste Group Bank upgraded shares of AbbVie from a “hold” rating to a “buy” rating in a research note on Wednesday, August 5th. Piper Sandler raised their price objective on shares of AbbVie from $298.00 to $303.00 and gave the stock an “overweight” rating in a report on Thursday, August 20th. Wells Fargo & Company upped their target price on shares of AbbVie from $295.00 to $300.00 and gave the company an “overweight” rating in a research note on Monday, August 17th. Sanford C. Bernstein reaffirmed a “market perform” rating on shares of AbbVie in a research report on Tuesday, June 23rd. Finally, UBS Group lifted their price target on AbbVie from $230.00 to $260.00 and gave the stock a “neutral” rating in a research note on Monday, July 13th. Two investment analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and five have issued a Hold rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $275.95.

AbbVie News Roundup

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: AbbVie submitted an application to the European Medicines Agency for subcutaneous induction of SKYRIZI in adults with moderately to severely active Crohn’s disease. The filing, supported by positive Phase 3 AFFIRM data, could expand SKYRIZI’s European Crohn’s disease label and offer patients a less invasive alternative to intravenous induction. AbbVie Submits Regulatory Application to EMA for SKYRIZI Subcutaneous Induction
• Positive Sentiment: The company’s inclusion in articles highlighting reliable dividend stocks reinforces AbbVie’s appeal to income-focused investors. Its dividend profile and defensive healthcare exposure may provide support, particularly during periods of economic or inflation uncertainty. 3 Dividend Stocks, 12 Paychecks a Year
• Positive Sentiment: Ken Griffin reportedly increased his AbbVie stake by 547% during the second quarter, signaling confidence from a prominent institutional investor in the company’s dividend and long-term prospects. Ken Griffin Increased His Stake in AbbVie
• Neutral Sentiment: AbbVie’s patient-support efforts, including an immunology scholarship program, strengthen its public-facing support initiatives but are unlikely to materially affect near-term earnings or valuation. AbbVie’s Immunology Scholarship Program
• Negative Sentiment: Valuation concerns may be limiting upside. AbbVie has rallied significantly and is trading at a premium, prompting debate over whether future growth from SKYRIZI and the broader pipeline can justify the stock’s price. Has AbbVie Stock Become Too Expensive to Buy?

Insider Transactions at AbbVie

In related news, EVP Nicholas Donoghoe sold 32,710 shares of the company’s stock in a transaction on Friday, August 14th. The stock was sold at an average price of $250.00, for a total transaction of $8,177,500.00. Following the completion of the transaction, the executive vice president directly owned 74,430 shares in the company, valued at $18,607,500. This represents a 30.53% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 0.06% of the stock is owned by corporate insiders.

AbbVie Price Performance

AbbVie stock opened at $258.23 on Friday. The company has a market cap of $456.24 billion, a PE ratio of 72.95, a P/E/G ratio of 0.87 and a beta of 0.30. The company has a fifty day moving average price of $251.87 and a two-hundred day moving average price of $228.68. AbbVie Inc. has a 12 month low of $190.75 and a 12 month high of $267.47.

AbbVie (NYSE:ABBV) last issued its earnings results on Friday, July 31st. The company reported $3.65 earnings per share for the quarter, topping analysts’ consensus estimates of $3.61 by $0.04. AbbVie had a net margin of 9.80% and a negative return on equity of 422.07%. The company had revenue of $16.99 billion for the quarter, compared to analysts’ expectations of $16.80 billion. During the same period in the prior year, the company earned $2.97 earnings per share. The firm’s revenue was up 10.2% compared to the same quarter last year. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. Equities research analysts anticipate that AbbVie Inc. will post 14.06 earnings per share for the current year.

AbbVie Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Friday, August 14th. Investors of record on Wednesday, July 15th were given a dividend of $1.73 per share. The ex-dividend date was Wednesday, July 15th. This represents a $6.92 dividend on an annualized basis and a yield of 2.7%. AbbVie’s payout ratio is currently 195.48%.

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.